<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00554502</url>
  </required_header>
  <id_info>
    <org_study_id>STOP-IgAN</org_study_id>
    <nct_id>NCT00554502</nct_id>
  </id_info>
  <brief_title>Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy</brief_title>
  <acronym>STOP-IgAN</acronym>
  <official_title>Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Evaluation of the efficacy of an immunosuppressive therapy added to a comprehensive
           supportive therapy to induce a clinical remission in patients at risk for progressive
           IgAN

        -  Investigation of differences between the treatments regarding the number of patients
           loosing more than 15 ml/min of GFR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The best treatment of glomerular diseases of the kidney is currently not well defined. This
      study aims to answer if in patients with IgA nephropathy, the most common type of
      glomerulonephritis an immunosuppressive treatment (with the use of steroids and chemotherapy)
      added to a supportive treatment is more effective than a supportive treatment alone (with the
      use of drugs lowering the blood pressure and the urinary protein loss).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients reaching full clinical remission of their disease</measure>
    <time_frame>at the end of the 3 year study period.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GFR loss of 15 ml/min or higher from baseline GFR</measure>
    <time_frame>at the end of the 3 year study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>-Absolute GFR-change.</measure>
    <time_frame>at the end of the 3 years study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GFR loss &gt;=30 ml/min from baseline GFR</measure>
    <time_frame>at the end of the 3 year study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Onset of end stage renal disease.</measure>
    <time_frame>at the end of the 3 years study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean annual change in one over serum creatinine concentration</measure>
    <time_frame>at the end of the 3 years study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria at 12 and 36 months</measure>
    <time_frame>12 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disappearance of microhematuria</measure>
    <time_frame>at the end of the 3 years study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>supportive therapy with: ACE-inhibitor / ARB / Statin</intervention_name>
    <description>Antihypertensive therapy with a target blood pressure below 125/75 mmHg (following current clinical guidelines).
ACE-inhibitors (ARB when an ACE-inhibitor is not tolerated)
Other antihypertensive medications depending on the clinical decision and following current guidelines.
Statin therapy
Dietary counseling for a low-sodium diet and, if GFR is below 60 ml/min, for a protein intake of 0.8 g/kg/day.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>supportive and immunosuppressive therapy</intervention_name>
    <description>supportive therapy as outlined above
depending on GFR:
methylprednisolone and prednisolone
cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone
Concomitant medication with the immunosuppressive treatment following current clinical practice</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients from 18-70 years with histologically proven primary IgAN with
             typical mesangioproliferative features. Diagnosis has to be made by a
             neuropathologist.

          -  Proteinuria above 0.75 g/day within 12 weeks prior to or at the first visit in the
             run-in phase (month -6)and presence of at least one further risk factor for the
             development of end stage renal disease

               1. arterial hypertension, defined as ambulatory blood pressure &gt;140/90 mm Hg or the
                  use of antihypertensive medication or

               2. impaired renal function, defined as creatinine clearance or estimated GFR &lt;90
                  ml/min.

        Exclusion Criteria:

          -  Known allergy or intolerance to study medication (except in case of ACE-inhibitor, in
             which case a change to an angiotensin receptor blocker is possible).

          -  Women who are pregnant or breastfeeding and women without sufficient contraception.

          -  Any prior immunosuppressive therapy.

          -  Variants of primary IgAN (e.g. rapidly progressive IgAN with crescents in &gt;50% of
             glomeruli or minimal change GN with glomerular IgA deposits).

          -  Significant liver dysfunction (more than three fold increased GPT compared to norm)

          -  Contraindication for immunosuppressive therapy, like

               -  acute or chronic infectious disease incl. hepatitis and HIV positive patients

               -  any malignancy

               -  leukocytopenia, thrombocytopenia or known allergy against prednisolone,
                  cyclophosphamide or azathioprine

               -  active intestinal bleeding, active gastric or duodenal ulcer

               -  Need of permanent immunosuppression, (e.g. transplanted patients,
                  steroid-dependent inflammatory diseases)

          -  Secondary IgAN or diseases associated with glomerular deposits of IgA.

          -  Additional other chronic renal disease.

          -  Creatinine clearance below 30 ml/min (mean of 3 measurements).

          -  Alcohol or drug abuse

          -  Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study

          -  Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to
             return for follow-up visits, and unlikelihood of completing the study

          -  Participation in a parallel clinical trial or participation in another clinical trial
             within the last 3 months.

          -  Subjects who are in any state of dependency to the sponsor or the investigators.

          -  Employees of the sponsor or the investigators.

          -  Subjects who have been committed to an institution by legal or regulatory order.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Floege, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Clinic II, University Hospital Aachen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Clinic II, University Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2. Medizinische Klinik, Nephrologie, Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus Charité Mitte, Medizinische Klinik - Schwerpunkt Nephrologie, Centrum 13</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum, Medizinische Klinik / Nephrologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios-Klinikum Berlin-Buch, Nephrologie Charité CCB</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Krankenhaus Medizinische Klinik II</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte, Medizinische Klinik III</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden, Medizinische Klinik III, Bereich Nephrologie</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Klinik für Nephrologie</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Medizinische Klinik IV</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Nieren- und Hochdruckkrankheiten</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Innere Medizin IV</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH, Medizinische Klinik und Poliklinik II</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Göttingen, Zentrum Innere Medizin, Abteilung für Nephrologie und Rheumatologie</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, 3. Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Abteilung Nephrologie</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Universitätsklinik Heidelberg, Nierenzentrum Heidelberg, Sektion Nephrologie</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Medizinische Klinik III</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum GmbH, Abteilung für Nephrologie und Transplantationsmedizin</name>
      <address>
        <city>Kaiserslautern</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln, Klinik IV für Innere Medizin, Nephrologie und Allgemeine Innere Medizin</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg, Klinik für Nephrologie, Zentrum für Innere Medizin</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum am Brand</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim, V. Medizinische Klinik</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Marburg, Klinik für Innere Medizin, Schwerpunkt Nephrologie</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Nierenzentrum</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der LMU, Nephrologisches Zentrum</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Medizinische Klinik II, Abteilung für Nephrologie</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Medizinische Klinik und Poliklinik D</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Klinik und Poliklinik für Innere Medizin II</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder, Abteilung Innere Medizin II</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Medizinische Klinik IV, Sektion für Nieren- und Hochdruckkrankheiten</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialyse-Zentrum Dres.med. PD H. Reichel, Th. Weinreich u. C.</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Nieren- und Hochdruckkrankheiten</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Würzburg, Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.stop-igan-study.rwth-aachen.de/</url>
    <description>Study Homepage</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2007</study_first_submitted>
  <study_first_submitted_qc>November 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2007</study_first_posted>
  <last_update_submitted>September 21, 2015</last_update_submitted>
  <last_update_submitted_qc>September 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2015</last_update_posted>
  <responsible_party>
    <name_title>Verena Deserno</name_title>
    <organization>Clinical Trials Centre Aachen</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

